Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 124.50 122.00 127.00 124.50 124.50 124.50 932 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 192

Amryt Pharma Share Discussion Threads

Showing 4826 to 4845 of 5375 messages
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
DateSubjectAuthorDiscuss
23/8/2019
11:20
https://www.law360.com/bankruptcy/articles/1191638/aegerion-pharma-s-ex-ceo-objects-to-ch-11-plan?nl_pk=c1b611ce-45ab-489e-a7e4-cc86bdbee3a4&utm_source=newsletter&utm_medium=email&utm_campaign=bankruptcy
alphabravo321
22/8/2019
16:50
Https://tinyurl.com/Amryt-Pharma Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper Amryt has a chance of being awarded a priority review voucher, which sell for several times more than the company’s current market cap
delta0091
22/8/2019
12:14
alphabravo321 5 Aug '19 - 16:48 - 4699 of 4712 0 0 0 Readmission doc due to be published in early Aug, readmission to trading planned for “early Q4” >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Where's this admissions doc, alphabravo? It's late August now and no sign of that bloody admissions doc. I can see the relisting date slipping into 2020.
papillon
22/8/2019
12:12
They do indeed, waterloo01.
papillon
22/8/2019
08:18
See Astra zenica bought a priority review voucher for $95m (down from some years ago). Don't AMYT have one of these if ap101 gets approval?
waterloo01
20/8/2019
18:16
hxxps://risemedia.net/2019/08/07/acromegaly-drug-market-top-competitors-are-silence-therapeutic-strongbridge-biopharma-plc-amryt-pharma-plc-foresee-pharmaceuticals-co-ltd-ipsen-pharma-and-others/ Acromegaly Drug Market Top Competitors are Silence Therapeutic, Strongbridge Biopharma plc, Amryt Pharma plc, Foresee Pharmaceuticals Co., Ltd, Ipsen Pharma and Others Acromegaly is a rare hormonal disorder also known as gigantism. It occurs when pituitary gland releases excessive growth hormone in the body due to the tumor formation in the pituitary gland. This abnormal production of growth hormone results in the bone enlargement. It mainly affects the geriatric population. Global Acromegaly Drug Market is rising gradually with a substantial CAGR of 5.10% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.
delta0091
19/8/2019
12:09
Well no new update from AMYT since the result of the AGM RNS dated 10th July. Will this drag into 2020 before AMYT relists? From my previous experience of AIM listed companies (including AMYT) they almost always never stick to the initial timetables.
papillon
12/8/2019
14:49
Yes Bermuda I heard of Amryt through Debra Ireland a few years ago. An excellent charity.
chica1
10/8/2019
17:03
DEBRA of America is a high profile Epidermolysis Bullosa medical research charity and they will be hosting their annual benefit evening in New York in October. Amryt is one of three companies (& the only non US one) being recognised with a Partners in Progress award to be presented on the night. Good stuff and well done Amryt. Https://debra.salsalabs.org/2019benefit/index.html
bermudashorts
10/8/2019
09:42
Hi Chica1....As per Newton’s Third Law - Every action has an equal and opposite reaction. Put simply, I have been on this site long enough to realise that Papillon is usually reacting to others comments, rather than irritating others as his primary objective. As for yourself, all the best with the medical condition which afflicts your family. EB is a nasty disease. Previous trials with episalvan have shown a 10% improvement in the skin healing; I would doubt that you would be able to notice significant improvement in a single participant study!
diamondstar1
09/8/2019
16:57
Yes Papillon everyone is anonymous here.I see from you recent posting that you seem to irritate people on every forum you partake in. Quite sad actually that these boards seem to be your only life!
chica1
06/8/2019
21:09
mdalos1 6 Aug '19 - 19:41 - 4702 of 4702 0 0 0 LOLs... absolutely clueless !! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Don't keep beating yourself up, MADLOSS! PMSL ROFLMAO
papillon
05/8/2019
18:44
As soon as the admission document was published FAST returned from suspension on the 31st March 2016 https://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/AIM-Restoration-Fastnet-Equity-plc/70943777 The acquisition of AMYT (an RTO) didn't become effective until 18th April 2016 when the company named changed to Amryt Pharma. https://uk.advfn.com/stock-market/london/fastnet-equity-FAST/share-news/Fastnet-Equity-PLC-Result-of-General-Meeting-and-C/71153871 Hence it's possible that AMYT could relist as soon the admission document is published in "early August" and before the Aegerion deal is finalised. Will it? No idea.
papillon
05/8/2019
16:03
Thanks. Going to be interesting. Not a bad thing being suspended anyhow given the markets.
waterloo01
05/8/2019
15:48
Readmission doc due to be published in early Aug, readmission to trading planned for "early Q4"
alphabravo321
05/8/2019
15:46
I've forgotten. What's the potential timetable re the merger?
waterloo01
05/8/2019
12:53
Any day now
alphabravo321
31/7/2019
15:17
You are, chica1, like the rest of us an anonymous poster so I have no idea whether you are telling the truth, or not. I must admit to finding it strange that one who does "not own any stocks" should be posting on a bb of a site, ADVFN, that caters solely for private investors. I'm surprised you even bothered to look for the site. Of course you are entitled to your opinion and if you are telling the truth and have found, in your experience, that Episalvan is not that effective (if at all) you might be the exception that proves the rule. After all that's no doubt why AMYT had to increase the size of the phase III trial and increase the patient numbers. I doubt if there is any drug, or treatment, currently on sale that is effective for every patient. We'll have to await the final phase III results to find out whether your experiences (if you are being truthful) with Episalvan are the exception, or the norm!
papillon
31/7/2019
15:05
mdalos1 31 Jul '19 - 00:19 - 4692 of 4693 0 0 0 POT KETTLE.... 100s of posts on here almost all of the time, relentlessly at times, including copy/pasting other people's posts AND having "arguments" here with Posters on an entirely different BB !!!! How ironic... LOLs Do you think you'll be down 65% or maybe as much as 75% when the dust settles ? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> ROFLMAO. PMSL. I thought I'd copy your words of wisdom (LOL) for posterity before you delete them! I make no prediction of the likely share price when they relist, MADLOSS, unlike you! You have nailed your colours to the mast. When they relist I can refer to this post to see if you were right, or wrong! PS. Every time I post on this bb, you follow suit, MADLOSS. Are you stalking me? If you want to get to know me better just post me a message and we can arrange to meet up somewhere. We can then have a little chat! Close up and personal! LOL
papillon
30/7/2019
23:29
I do not own any stocks. I am probably here for selfish reasons in the hope of relief for the condition that afflicts my family.
chica1
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200127 09:49:40